The global neurostimulation devices market size valued at $5.47 billion in 2020 and expected to reach $10.96 billion in 2027, growing at a CAGR of 11.8% during forecast period 2021-2027. For the treatment of chronic pain, movement problems, epilepsy, and Parkinson’s disease, neurostimulation devices administer electrical stimulation to specific regions of the patient’s brain, spinal cord, or peripheral nervous system. Spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, and cortical stimulators are among the neurostimulation devices. High cost, device malfunctions, and stringent regulatory policies are projected to restrain the growth of the market over the forecast period. For instance, in February 2014, TGA gave hazard alert to Medtronic’s deep brain and spinal cord stimulation systems due to unexpected loss of stimulation and over-stimulation of the devices in the Australia. This report studies neurostimulation devices market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, neurostimulation devices market report includes recent product launches, regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analysed neuromodulation devices market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities).